# Screening Plasma HER2 Amplication by Digital PCR in Advanced Breast Cancer Patients Treated With Trastuzumab and Pyrotinib

> **NCT05020964** · PHASE2 · UNKNOWN · sponsor: **Chinese Academy of Medical Sciences** · enrollment: 68 (estimated)

## Conditions studied

- Advanced Breast Cancer

## Interventions

- **DRUG:** Trastuzumab and Pyrotinib

## Key facts

- **NCT ID:** NCT05020964
- **Lead sponsor:** Chinese Academy of Medical Sciences
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-08-20
- **Primary completion:** 2022-09-01
- **Final completion:** 2023-09-01
- **Target enrollment:** 68 (ESTIMATED)
- **Last updated:** 2021-08-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05020964

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05020964, "Screening Plasma HER2 Amplication by Digital PCR in Advanced Breast Cancer Patients Treated With Trastuzumab and Pyrotinib". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT05020964. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*